Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts
Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera · 2024
Read Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts by Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11600434.txt.
Description
Mario Cazzola and three co-authors review the new generation of anti-inflammatory drugs for chronic obstructive pulmonary disease, asking what each does to the heart, in this 2024 article. COPD and cardiovascular disease travel together, sharing inflammatory roots, and many patients die of the second while being treated for the first. A drug that calms the lungs but strains the heart would be a poor bargain.
The classes under review differ sharply. Inhibiting one phosphodiesterase type risks rhythm problems, while its sibling type seems to protect vessels and reduce clots. Kinase blockers aimed at lung inflammation also cut cardiac scarring in the data reviewed. The antibody drugs, precision strikes on single immune messengers, reduce flare-ups but demand heart monitoring because of their immune effects. The review's message is accountancy: every new lung drug should be booked with its cardiovascular assets and liabilities on the same page.
Catalog record
| CREATOR | Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |